Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*
Year: 2021
Type: article
Study design: Observational Study
Abstract: In acute myeloid leukaemia (AML) t(8;16)(p11;p13)/MYST3-CREBBP is a very rare abnormality. Previous small series suggested poor outcome. We report on 59 patients with t(8;16) within an international, collaborative study. Median age was 52 (range: 16-75) years. AML was de novo in 58%, therapy-related (t-AML) in 37% and secondary after myelodysplastic syndrome (s-AML) in 5%. Cytogenetics revealed a complex karyotype in 43%. Besides MYST3-CREBBP, whole-genome sequencing on a subset of 10 patients revealed recurrent mutations in ASXL1, BRD3, FLT3, MLH1, POLG, TP53, SAMD4B (n = 3, each), EYS, KRTAP9-1 SPTBN5 (n = 4, each), RUNX1 and TET2 (n = 2, each). Complete remission after intensive chemotherapy was achieved in 84%. Median follow-up was 5·48 years; five-year survival rate was 17%. Patients with s-/t-AML (P = 0·01) and those with complex karyotype (P = 0·04) had an inferior prognosis. Allogeneic haematopoietic cell transplantation (allo-HCT) was performed in 21 (36%) patients, including 15 in first complete remission (CR1). Allo-HCT in CR1 significantly improved survival (P = 0·04); multivariable analysis revealed that allo-HCT in CR1 was effective in de novo AML but not in patients with s-AML/t-AML and less in patients exhibiting a complex karyotype. In summary, outcomes of patients with t(8;16) are dismal with chemotherapy, and may be substantially improved with allo-HCT performed in CR1.
Source: British Journal of Haematology
DOI: 10.1111/bjh.17336
Authors: Sabine Kayser, Robert K. Hills, Ralitsa Langova, Michael Kramer, Francesca Guijarro, Zuzana Sustkova, Elihu H. Estey, Carole M. Shaw, Zdeněk Ráčil, Jiri Mayer, Pavel Zak, Maria R. Baer, Andrew M. Brunner, Tomas Szotkowski, Petr Cetkovsky, David Grimwade, Roland B. Walter, Alan K. Burnett, Anthony D. Ho, Gerhard Ehninger, Carsten Müller‐Tidow, Uwe Platzbecker, Christian Thiede, Christoph Röllig, Angela Schulz, Gregor Warsow, Benedikt Brors, Jordi Esteve, Nigel H. Russell, Richard F. Schlenk, Mark J. Levis
Institutions: German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, National Center for Tumor Diseases, University Hospital Leipzig, University of Oxford, University Hospital Carl Gustav Carus, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Masaryk University, University Hospital Brno, University of Washington, Fred Hutch Cancer Center, Institute of Haematology and Blood Transfusion, Charles University, University Hospital Hradec Králové, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Massachusetts General Hospital, University Hospital Olomouc, Palacký University Olomouc, King's College London, Cardiff University, Deutsches Konsortium für Translationale Krebsforschung, Nottingham University Hospitals NHS Trust, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,600
Awards: G2169464185, G2947552126
OpenAlex ID: W3126736617